Acuta Capital Partners is based out of Redwood City. Acuta Capital Partners is a hedge fund with 3 clients and discretionary assets under management (AUM) of $244,228,617 (Form ADV from 2024-03-27). Their last reported 13F filing for Q1 2025 included $86,228,809 in managed 13F securities
and a top 10 holdings concentration of 64.54%. Acuta Capital Partners's largest holding is Ocular Therapeutix Inc with shares held of 1,219,724. Whalewisdom has at least 42 13F filings, 2 13D filings, and 62 13G filings
Business Description
Acuta Capital Partners, LLC ("Acuta"), a Delaware limited liability company formed in July of 2011, provides investment management services to Clients. Acuta is principally owned by Anupam Dalal, who serves as the Managing Member and Chief Investment Officer. Scott Smith is the Chief Compliance Officer and Chief Operating Officer. Acuta provides investment management services, directly or through its affiliates, to several privately-offered pooled investment vehicles (the "Funds").
Acuta provides investment advice and management to privately placed investment funds, including Acuta Opportunity Fund, LP ("Acuta Opportunity Fund") and Acuta Capital Fund. Advisory services are tailored to achieve the Clients’ investment objectives as described more fully in each Fund’s offering memorandum and governing documents. Acuta generally has the authority to select which and how many securities and other instruments to buy or sell without consultation with the Clients or their Investors.
Investment Strategy
Acuta's investment philosophy is based on bottom-up analysis, absolute-value oriented investing, and a long-term perspective. Acuta believes that business fundamentals convey useful information and employs a bottom-up strategy to identify individual investment opportunities through fundamental analysis. This includes analyzing reports, interviewing management, customers, and competitors, and performing in-depth industry diligence to assess the risk-return profile of an investment.
Acuta intends to employ a value approach to investing that is risk averse and focused on preserving capital over the long run. While Anupam Dalal, the Chief Investment Officer of Acuta, has experience in health care, the most important investment criterion is an in-depth understanding of the factors that might cause a company or security to be particularly undervalued in the market. Acuta invests in securities of small-cap and mid-cap issuers, which may present greater risks than those of large-cap issuers.
Owners
- THE LIN-LAY FAMILY 2007 TRUST DATED SEPTEMBER 7, 2007 - MEMBER
- SMITH, SCOTT, RANDALL - CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
- DALAL, ANUPAM, AKSHAY - MANAGING MEMBER, CHIEF INVESTMENT OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| SLNO Soleno Therapeutics | 5.56% |
| OCS Oculis Holding AG | 2.76% |
| TRVI Trevi Therapeutics I | 2.53% |
| MRK Merck & Co Inc | 2.39% |
| SRZN Surrozen, Inc | 2.3% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| CRNX Crinetics Pharmaceut | 6.32% |
| PCVX Vaxcyte, Inc | 3.71% |
| RVMD Revolution Medicines | 2.18% |
| MRSN Mersana Therapeutics | 1.61% |
| TSHA Taysha Gene Therapie | 1.54% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| OCUL Ocular Therapeutix I | 10.37% |
| INSM Insmed Inc | 9.38% |
| TRML Tourmaline Bio Inc | 7.53% |
| WHWK Whitehawk Therapeuti | 7.04% |
| ELVN Enliven Therapeutics | 6.05% |
2025-03-31
13F Activity
| Market Value | $86.2m, Prior: $99.4m |
| Inflows (Outflows) as % of Total MV | +1.638% |
| New Purchases | 6 stocks |
| Added To | 19 stocks |
| Sold out of | 12 stocks |
| Reduced holdings in | 6 stocks |
| Top 10 Holdings % | 64.54% |
| Turnover %[1] | 40% |
| Turnover Alt %[2] | 24.58% |
| Time Held Top 20 | 2.8 quarters |
| Time Held Top 10 | 1.6 quarters |
| Time Held All | 3.76 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31